Health economics of prevention of coronary heart disease and vascular events: a cost-effectiveness analysis based on the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

J Hum Hypertens. 2001 Aug:15 Suppl 1:S53-6. doi: 10.1038/sj.jhh.1001086.

Authors

B Jönsson¹, M Buxton, P Hertzman, T Kahan, N Poulter; Anglo-Scandinavian Cardiac Outcomes Trial, Health Economics Working Group

Affiliation

¹ Stockholm School of Economics, Box 6501, S-113 83 Stockholm, Sweden. Bengt.Jonsson@hhs.se

PMID: 11685911
DOI: 10.1038/sj.jhh.1001086

No abstract available

MeSH terms

Adrenergic beta-Antagonists / therapeutic use
Aged
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use
Calcium Channel Blockers / therapeutic use
Coronary Disease / drug therapy
Coronary Disease / economics*
Cost-Benefit Analysis / economics
Diuretics / therapeutic use
Humans
Hypercholesterolemia / drug therapy
Hypercholesterolemia / economics*
Hypertension / drug therapy
Hypertension / economics*
Middle Aged
Regression Analysis
Reproducibility of Results

Substances

Adrenergic beta-Antagonists
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Calcium Channel Blockers
Diuretics